Glaucoma: Current and Future Trends
Sponsored by: GlobalData
- Glaucoma Treatment And Epidemiology
- Glaucoma Unmet Needs
- Drug Forecast
Date: 27 February
Days to go: 5
Time: 4PM London/11AM New York
This expert presentation is an invitation-only event, open to GlobalData's clients and per invitation. The webinar recording and presentation will be available on GlobalData's Pharmaceutical Intelligence Center. For any requests or questions about this webinar please contact firstname.lastname@example.org.
Glaucoma is the leading cause of irreversible vision loss. The term glaucoma includes many different diseases, which are associated with differing risk factors, symptoms, treatment, and prognosis. All forms of glaucoma are characterized by the loss of the retinal ganglion cells and their axons that make up the optic nerve, which results in a cupping of the optic nerve head. This leads to optic nerve damage and visual field loss. Raised intraocular pressure (IOP) is the primary risk factor for glaucoma, and treatment options for glaucoma are focused primarily on lowering the IOP.
The treatment landscape for glaucoma has remained relatively unchanged over the last 15–20 years; however the glaucoma drug pipeline suggests there has been a shifting trend in corporate strategy which could result in the approval of several new classes of products. The recent approval of Rho kinase inhibitors in the US and Japan marks the first new class of glaucoma drugs to be approved for over a decade, and the ongoing Phase III trials for sustained-release (SR) implants appear poised to provide some promising new formulations of glaucoma drugs in the near future.
In this presentation Dr. Thomas Moore, a Healthcare Analyst at GlobalData, will present the changing glaucoma treatment landscape between 2016 and 2026, drawing on insights from GlobalData's recently published report, PharmaPoint: Glaucoma – Global Drug Forecast and Market Analysis to 2026. The current treatment options and drug pipeline for glaucoma will be covered, including a discussion on GlobalDat's sales forecast for the glaucoma market. The webinar will include insights from KOLs covering the most important unmet needs for glaucoma, as well as the opportunities which are likely to remain by the end of the forecast period. Dr. Christopher Pace, a Therapy Area Director at GlobalData, will moderate a Q&A session following the presentation.
Thomas Moore, PhD is a Healthcare Analyst at GlobalData in London. Since joining GlobalData in 2016. Thomas has worked across several therapy areas, providing market commentary and analysis through both primary and secondary research, and extensive disease market forecasting. Thomas’ areas of expertise include infectious diseases and ophthalmology, having published reports and briefs covering C. difficile infections, Glaucoma, HIV, and influenza vaccines. He received his PhD from the University of Sussex; where he also carried out his undergraduate MChem studies. Thomas’s doctoral research focused on the development of inhibitors of protein-protein interactions, and he worked both as a synthetic organic chemist, and as a computational chemist, modelling drug-protein interactions. As a doctoral student at the University of Sussex, Thomas spent one term as the elected student representative on university council, and also tutored high-school and college level science, including the running of weekly medicinal chemistry training sessions for doctoral students.
Christopher J. Pace,
Therapy Area Director
Christopher J. Pace, PhD, is a Therapy Area Director at GlobalData in Boston, where he primarily oversees the infectious diseases portfolio of syndicated market research reports and has also managed projects in the immunology and ophthalmology spaces. Since joining GlobalData in 2013, Dr. Pace has extensively researched and provided in-depth analysis and commentary on a wide range of topics within the infectious diseases space and across the pharmaceutical and healthcare industries, with areas of expertise including hepatitis C and HIV therapeutics, vaccine R&D and immunization policy, and antibiotics. Dr. Pace holds a PhD in Chemistry from Boston College and a BS in Chemistry from Fairfield University. Dr. Pace's doctoral research focused on the use of unnatural amino acids as tools for examining the fundamental energetics of aromatic interactions in proteins. While at Boston College, Christopher tutored college-level chemistry and biochemistry in the greater Boston area, and he also served as the Boston College Campus Representative for the Northeastern Section Younger Chemists Committee (NSYCC).
Key Learning Objectives
- Learn how GlobalData expects the glaucoma market landscape to change between 2016 and 2026 across the 7 major markets (US, France, Germany, Italy, Spain, the UK and Japan).
- Gain insight on the late-stage pipeline for Glaucoma, including which products GlobalData expects to succeed, and why.
- Learn which unmet needs KOLs identified in the glaucoma treatment landscape, and whether or not they are likely to be met by the current pipeline.
- Identify which companies are set to be the major players in glaucoma during the forecast period.
- Senior Managers
- Associate Directors
- Directors of Market Research
- Business Insights
- Market Intelligence
- Strategic Insights
- Pipeline Management
- Competitive Strategy
- Customer Insights
- Heads of Research and Development
- Heads of Product Planning and Marketing
- Brand Managers